Heart failure & cardiomyopathiesSecondary analysis
Lactate Dehydrogenase and Outcomes in Patients With Heart Failure (HF) and Reduced Ejection Fraction
- Secondary analysis of the GALACTIC-HF randomised trial
- phase 3
- placebo-controlled
Authors' conclusion
In GALACTIC-HF, higher LDH levels were independently associated with a higher risk of clinical outcomes in HFrEF.
Study context
- Population
- Patients with heart failure and reduced ejection fraction (HFrEF) in GALACTIC-HF (omecamtiv mecarbil vs placebo) with baseline lactate dehydrogenase (LDH)6,138 outpatients
- Participants
- 8,179 patients
- Comparison
- LDH quartiles
- Primary endpoint
- First HF event or CV death
Primary result
As reported in the abstract
Each group vs Q1Hazard ratio (95% CI)
Q2
1.15(1.02–1.31)
Q3
1.39(1.23–1.58)
Q4
1.84(1.62–2.08)
Further findings
Incremental prognostic value over PREDICT-HF model
- Baseline LDH improved Harrell's C statistic, integrated discrimination index (IDI) and net reclassification index (NRI) for the primary outcome
Baseline characteristics by LDH
- Higher LDH: more often female, worse HF status, higher creatinine, liver enzymes, creatine kinase, NT-proBNP and hs-troponin I
Original publication
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction. JACC Heart Fail. Published 13 January 2026. doi:10.1016/j.jchf.2025.102900
Summarised from the published abstract; every number is checked against it